| Miss Ashley Brooks Trombley, CNS | |
|
1923 S Utica Ave, Tulsa, OK 74104-6520 | |
| (918) 748-7650 | |
| (918) 403-6348 |
| Full Name | Miss Ashley Brooks Trombley |
|---|---|
| Gender | Female |
| Speciality | Certified Clinical Nurse Specialist (cns) |
| Experience | 21 Years |
| Location | 1923 S Utica Ave, Tulsa, Oklahoma |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467499319 | NPI | - | NPPES |
| 200039170A | Medicaid | OK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364S00000X | Clinical Nurse Specialist | R0073063 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St John Medical Center, Inc | Tulsa, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St John Physicians Inc | 2567366495 | 223 |
News Archive
Concord Medical Services Holdings Limited ("CMS" or "the Company"), operator of the largest network of radiotherapy and diagnostic imaging centers in China in terms of revenues and the total number of centers in operation in 2008, announced today that its initial public offering of 12,000,000 American Depositary Shares ("ADSs"), each representing three ordinary shares of the Company, was priced at $11.00 per ADS.
Cancer Research UK scientists have discovered how a combination of two chemotherapy drugs - already showing promise in clinical trials - destroys pancreatic cancer cells, according to research published in Cancer Discovery.
In children, primary spinal tumors comprise 4% of all tumors from the central nervous system. Spinal tumors can present with a variety of clinical signs and symptoms in children such as pain followed by motor regression, gait disturbance, sphincter dysfunction, sensory symptoms, torticollis, and kyphoscoliosis.
Combining intratumoral electroporation of interleukin-12 (IL-12) DNA (tavokinogene telseplasmid, or TAVO) with the immune checkpoint inhibitor pembrolizumab (Keytruda) led to clinical responses in patients with immunologically quiescent advanced melanoma, according to results from a phase II trial.
TriLink BioTechnologies, Inc. was recently awarded a Phase I SBIR Grant of approximately $100,000 by the National Institutes of Health to develop a Hot Start approach for Ligase Chain Reaction (LCR). Hot Start LCR will employ chemically modified ligation components containing thermolabile protecting groups to eliminate common performance problems seen in LCR, such as false-positive signals and non-specificity.
› Verified 6 days ago
| Entity Name | St John Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336194406 PECOS PAC ID: 2567366495 Enrollment ID: O20031121000867 |
News Archive
Concord Medical Services Holdings Limited ("CMS" or "the Company"), operator of the largest network of radiotherapy and diagnostic imaging centers in China in terms of revenues and the total number of centers in operation in 2008, announced today that its initial public offering of 12,000,000 American Depositary Shares ("ADSs"), each representing three ordinary shares of the Company, was priced at $11.00 per ADS.
Cancer Research UK scientists have discovered how a combination of two chemotherapy drugs - already showing promise in clinical trials - destroys pancreatic cancer cells, according to research published in Cancer Discovery.
In children, primary spinal tumors comprise 4% of all tumors from the central nervous system. Spinal tumors can present with a variety of clinical signs and symptoms in children such as pain followed by motor regression, gait disturbance, sphincter dysfunction, sensory symptoms, torticollis, and kyphoscoliosis.
Combining intratumoral electroporation of interleukin-12 (IL-12) DNA (tavokinogene telseplasmid, or TAVO) with the immune checkpoint inhibitor pembrolizumab (Keytruda) led to clinical responses in patients with immunologically quiescent advanced melanoma, according to results from a phase II trial.
TriLink BioTechnologies, Inc. was recently awarded a Phase I SBIR Grant of approximately $100,000 by the National Institutes of Health to develop a Hot Start approach for Ligase Chain Reaction (LCR). Hot Start LCR will employ chemically modified ligation components containing thermolabile protecting groups to eliminate common performance problems seen in LCR, such as false-positive signals and non-specificity.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Miss Ashley Brooks Trombley, CNS 1923 S Utica Ave, Tulsa, OK 74104-6520 Ph: (918) 403-6348 | Miss Ashley Brooks Trombley, CNS 1923 S Utica Ave, Tulsa, OK 74104-6520 Ph: (918) 748-7650 |
News Archive
Concord Medical Services Holdings Limited ("CMS" or "the Company"), operator of the largest network of radiotherapy and diagnostic imaging centers in China in terms of revenues and the total number of centers in operation in 2008, announced today that its initial public offering of 12,000,000 American Depositary Shares ("ADSs"), each representing three ordinary shares of the Company, was priced at $11.00 per ADS.
Cancer Research UK scientists have discovered how a combination of two chemotherapy drugs - already showing promise in clinical trials - destroys pancreatic cancer cells, according to research published in Cancer Discovery.
In children, primary spinal tumors comprise 4% of all tumors from the central nervous system. Spinal tumors can present with a variety of clinical signs and symptoms in children such as pain followed by motor regression, gait disturbance, sphincter dysfunction, sensory symptoms, torticollis, and kyphoscoliosis.
Combining intratumoral electroporation of interleukin-12 (IL-12) DNA (tavokinogene telseplasmid, or TAVO) with the immune checkpoint inhibitor pembrolizumab (Keytruda) led to clinical responses in patients with immunologically quiescent advanced melanoma, according to results from a phase II trial.
TriLink BioTechnologies, Inc. was recently awarded a Phase I SBIR Grant of approximately $100,000 by the National Institutes of Health to develop a Hot Start approach for Ligase Chain Reaction (LCR). Hot Start LCR will employ chemically modified ligation components containing thermolabile protecting groups to eliminate common performance problems seen in LCR, such as false-positive signals and non-specificity.
› Verified 6 days ago
Teressa Headrick Lemaster, CNS Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 1705 E 19th St, Suite 302, Tulsa, OK 74104 Phone: 918-748-7585 Fax: 918-748-7539 | |
Lisa Darcell Davis, APRN-CNS Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 6161 S Yale Ave, Suite A100, Tulsa, OK 74136 Phone: 918-494-8500 Fax: 918-307-5578 | |
Suzanne Kirby, Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 1145 S Utica Ave Ste 1105, Tulsa, OK 74104 Phone: 918-579-5749 | |
Kristin Mariah Pruitt, APRN-CNS Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 1265 S Utica Ave, Suite 300, Tulsa, OK 74104 Phone: 918-592-0999 Fax: 918-592-1021 | |
Ruth Ann Fritz, CNS Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 6465 S Yale Ave Ste 401, Tulsa, OK 74136 Phone: 918-561-6141 Fax: 918-582-3593 | |
Tammy Irene Joplin, APRN Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 1923 S Utica Ave, Tulsa, OK 74104 Phone: 918-744-2769 | |
Julia Anne Jackson, APRN Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 1422 E 71st St Ste B, Tulsa, OK 74136 Phone: 918-710-0422 Fax: 918-949-6681 |